成都圣诺生物科技股份有限公司 2025年度业绩预告

Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 152.28 million and 190.35 million CNY, representing an increase of 102.26 million to 140.33 million CNY compared to the previous year, which is a year-on-year increase of 204.42% to 280.53% [3] - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 148.73 million and 185.91 million CNY, reflecting an increase of 103.11 million to 140.30 million CNY compared to the previous year, which is a year-on-year increase of 226.07% to 307.58% [3] - The previous year's net profit attributable to shareholders of the parent company was 50.02 million CNY, with a total profit of 61.51 million CNY [5] Group 2 - The significant increase in performance is attributed to the company's focus on its annual business strategy, the successful implementation of its production capacity, and the continuous expansion of domestic and international markets, leading to a sustained growth in demand for its peptide raw material business [6] - The performance forecast has not been audited by a registered accountant, and the data provided is based on preliminary calculations by the company's financial department [4][8]